Suppression of transforming growth factor-β1 gene expression by danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin-induced diabetic rats

Hormone and Metabolic Research

Volumn 38, Issue 2, 2006, Pages 82-88

  Zhang, Y W ^a   Xie, D ^a   Xia, B ^a   Zhen, R T ^a   Liu, I M ^b   Cheng, Juei Tang ^c  

^a WUHAN UNIVERSITY   (China)

^b TAJEN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Angelica sinensis; Angiotensin II; Astragalus membranaceus; Benazepril; Danggui buxue tang; Nephropathy; Type 1 diabetes

Indexed keywords

ALBUMIN; ANGIOTENSIN II; BENAZEPRIL; BETA 2 MICROGLOBULIN; CHINESE DRUG; CHOLESTEROL; CREATININE; DANGGUI BUXUE TANG; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; MESSENGER RNA; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOLESCENT; ANGELICA SINENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTRAGALUS MEMBRANACEUS; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; ERYTHROPOIESIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY MASS; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ASTRAGALUS MEMBRANACEUS; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; KIDNEY CORTEX; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANGELICA SINENSIS; ANIMALIA; ASTRAGALUS MEMBRANACEUS;

EID: 33645702760     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-925118     Document Type: Article

References (28)

1. Ning L, Chen CX, Jin RM, Wu YP, Zhang HG, Sun CL, Song CQ, Hu ZB. Effect of components of dang-gui-bu-xue decoction on hematopenia. Zhongguo Zhong Yao Za Zhi 2002; 27: 50-53
2. Song ZH, Ji ZN, Lo CK, Dong TT, Zhao KJ, Li OT, Haines CJ, Kung SD, Tsim KW. Chemical and biological assessment of a traditional Chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis: orthogonal array design to optimize the extraction of chemical constituents. Planta Med 2004; 70: 1222-1227
3. Hsieh CC, Lin WC, Lee MR, Hsu SL, Liu HS, Kao ST, Hsieh MT. Dang-Gui-Bu-Xai-Tang modulated the immunity of tumor bearing mice. Immunopharmacol Immunotoxicol 2003; 25: 259-271
4. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003; 10: 465-476
5. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003; 26: 2150-2155
6. Makino H, Nakamura Y, Wada J. Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26: 515-519
7. Cai Q, Li X, Wang H. Astragali and Angelica protect the kidney against ischemia and reperfusion injury and accelerate recovery. Chin Med J (Engl) 2001; 114: 119-123
8. Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS. Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 2002; 13: 302-312
9. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transpl 2003; 18: 1716-1725
10. Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, Walsh J, Deeg M, Pratt JH, March KL, Monnier VM, Weiss MF, Baynes JW, Peterson R. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 2000; 57: 92-104
11. Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 2001; 16: 1382-1386
12. Peng A, Gu Y, Lin SY. Herbal treatment for renal diseases. Ann Acad Med Singapore 2005; 34: 44-51
13. Schrijvers BF, DeVriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010
14. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284: 243-252
15. Miyazono K. TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev 2000; 11: 15-22
16. Cruzado JM, Lloberas N, Torras J, Riera M, Filial C, Herrero-Fresneda I, Aran JM, Alperovich G, Vidal A, Grinyo JM. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004; 53: 1119-1127
17. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-beta, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001; 158: 1653-1663
18. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator. J Am Soc Nephrol 2004; 15: S55-S57
19. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 2001; 345: 870-878
20. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-1747
21. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019
22. Tian YC, Fraser D, Attisano L, Phillips AO. TGF-beta1-mediated alterations of renal proximal tubular epithelial cell phenotype. Am J Physiol Renal Physiol 2003; 285: 130-142
23. Monkawa T, Hiromura K, Wolf G, Shankland SJ. The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27. J Am Soc Nephrol 2002; 13: 1172-1178
24. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824
25. Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Chin Med J 1998; 111: 17-23
26. Yu L, Li JZ, Wang HY. Research on the application of astragali and angelica in treating renal disease and its mechanisms. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001; 21: 396-399
27. Cheng JT. Review: drug therapy in Chinese traditional medicine. J Clin Pharmacol 2000; 40: 445-450
28. Huang WH, Song CQ. Research progresses in the chemistry and pharmacology of Angelica sinensis (Oliv.) Diel. Zhongguo Zhong Yao Za Zhi 2001; 26: 47-151